Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 4/20 | 0.48 |
| ▸ | CHKA | P35790 | 3/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | NT5E | P21589 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | P2RY1 | P47900 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL21050256 | 1.00 | AHCY (0.48) | AHCYCHKACA5ANT5ELMNA | |
| Phosphoric Acid SCHEMBL21050313 | 0.88 | P2RY1 (0.36) | AHCYCHKACA5ANT5EP2RY1 | |
| Phosphoric Acid SCHEMBL21050274 | 0.88 | P2RY1 (0.49) | CHKANT5EADORA3ADORA2AADORA1 | |
| Phosphoric Acid SCHEMBL21050227 | 0.88 | P2RY1 (0.49) | CHKANT5EADORA3ADORA2AADORA1 | |
| Phosphoric Acid SCHEMBL21050309 | 0.88 | P2RY1 (0.36) | AHCYCHKACA5ANT5EP2RY1 | |
| Phosphoric Acid SCHEMBL21050312 | 0.83 | NT5E (0.42) | AHCYNT5EADORA3ADORA1P2RY1 | |
| Phosphoric Acid SCHEMBL21050258 | 0.83 | NT5E (0.42) | AHCYNT5EADORA3ADORA1P2RY1 | |
| SCHEMBL21050318 | 0.82 | AHCY (0.52) | AHCYCHKACA5ANT5ELMNA | |
| Phosphoric Acid SCHEMBL21050276 | 0.82 | PNP (0.52) | NT5EADORA3 | |
| Phosphoric Acid SCHEMBL21050235 | 0.82 | PNP (0.52) | NT5EADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040975-B2 | Carbocyclic nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-06-22 | — | — | US | claimed |
| US-20190177326-A1 | CARBOCYCLIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-06-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040975-B2 | Carbocyclic nucleoside reverse transcriptase inhibitors | SAMHD1, POLRMT, RNGTT | AHCY 206/4885CHKA 977/4885CA5A 1740/4885 |
| US-20190177326-A1 | CARBOCYCLIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | SAMHD1, POLRMT, RNGTT | AHCY 206/4885CHKA 977/4885CA5A 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.